Methods For The Prophylaxis And/or Treatment Of Thromboembolic Disorders By Combination Therapy With Substituted Oxazolidinones
2 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to combinations of A) oxazolidinones of formula (I) and B) other active ingredients, to a method for producing said combinations and to the use thereof as medicaments, in particular for the treatment and/or prophylaxis of thrombo-embolic diseases.
-
Citations
19 Claims
-
1-9. -9. (canceled)
-
10. A method for the prophylaxis and/or treatment of thromboembolic disorders comprising administering to a subject in need thereof an effective amount of a combination comprising
A) at least one compound of the formula (I) in which R1 is 2-thiophene which is substituted in position 5 by a radical selected from chlorine, bromine, methyl and trifluoromethyl, R2 is D-A-: -
where; the radical “
A”
is phenylene;the radical “
D”
is a saturated 5- or 6-membered heterocycle which is linked via a nitrogen atom to “
A”
, andwhich has a carbonyl group directly adjacent to the linking nitrogen atom, and in which a ring carbon member may be replaced by a heteroatom selected from the series S, N and O; where the group “
A”
defined above may optionally be substituted once or twice in the meta position relative to the linkage to the oxazolidinone by a radical selected from fluorine, chlorine, nitro, amino, trifluoromethyl, methyl and cyano,R3, R4, R5, R6, R7 and R8 are hydrogen, or a pharmaceutically acceptable salt or hydrate thereof, or their mixture and B) at least one further active pharmaceutical ingredient. - View Dependent Claims (11, 12, 13)
or a pharmaceutically acceptable salt or hydrate thereof, or their mixture. -
12. The method of claim 10, wherein the further active pharmaceutical ingredient B) is a platelet aggregation inhibitor, anticoagulant, fibrinolytic, lipid-lowering agent, coronary therapeutic agent and/or vasodilator.
-
13. The method of claim 11, wherein the further active pharmaceutical ingredient B) is a platelet aggregation inhibitor, anticoagulant, fibrinolytic, lipid-lowering agent, coronary therapeutic agent and/or vasodilator.
-
-
14. A method for the prophylaxis and/or treatment of myocardial infarction, angina pectoris, sudden heart death, reocclusions and restenoses after angioplasty or aortocoronary bypass, stroke, transient ischemic attacks, peripheral arterial occlusive diseases, pulmonary embolisms or deep venous thromboses comprising administering to a subject in need thereof an effective amount of a combination comprising
A) at least one compound of the formula (I) in which R1 is 2-thiophene which is substituted in position 5 by a radical selected from chlorine, bromine, methyl and trifluoromethyl, R2 is D-A-: -
where; the radical “
A”
is phenylene;the radical “
D”
is a saturated 5- or 6-membered heterocycle which is linked via a nitrogen atom to “
A”
, andwhich has a carbonyl group directly adjacent to the linking nitrogen atom, and in which a ring carbon member may be replaced by a heteroatom selected from the series S, N and O; where the group “
A”
defined above may optionally be substituted once or twice in the meta position relative to the linkage to the oxazolidinone by a radical selected from fluorine, chlorine, nitro, amino, trifluoromethyl, methyl and cyano,R3, R4, R5, R6, R7 and R8 are hydrogen, or a pharmaceutically acceptable salt or hydrate thereof, or their mixture and B) at least one further active pharmaceutical ingredient. - View Dependent Claims (15, 16, 17, 18, 19)
or a pharmaceutically acceptable salt or hydrate thereof, or their mixture. -
16. The method of claim 14, wherein the further active pharmaceutical ingredient B) is a platelet aggregation inhibitor, anticoagulant, fibrinolytic, lipid-lowering agent, coronary therapeutic agent and/or vasodilator.
-
17. The method of claim 15, wherein the further active pharmaceutical ingredient B) is a platelet aggregation inhibitor, anticoagulant, fibrinolytic, lipid-lowering agent, coronary therapeutic agent and/or vasodilator.
-
18. The method of claim 14, wherein the method is for the prophylaxis and/or treatment of angina pectoris that is unstable angina.
-
19. The method of claim 15, wherein the method is for the prophylaxis and/or treatment of angina pectoris that is unstable angina.
-
Specification